Last reviewed · How we verify
Background Therapy
Background Therapy is a general term referring to the standard or baseline treatment regimen used as a control or foundation in clinical studies, rather than a specific drug with a defined mechanism.
At a glance
| Generic name | Background Therapy |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Background Therapy does not refer to a single pharmaceutical agent but rather to the existing or standard treatment that patients receive as part of a clinical trial protocol. It serves as the comparator or foundation upon which investigational therapies are added or compared. The specific mechanism depends entirely on what drugs comprise the background regimen.
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038) (PHASE3)
- A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition (PHASE3)
- Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18) (PHASE1)
- Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis (PHASE2)
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) (PHASE3)
- A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |